Trafalgar International (GCAN) Total Non-Current Liabilities (2016 - 2021)
Trafalgar International (GCAN) posted Total Non-Current Liabilities of $460651.0 for Q1 2021, up 4.11% on a QoQ basis from $442467.0 in Q4 2020, and down 53.71% year-over-year from $995119.0 in Q1 2020.
Analysis
Trafalgar International (GCAN) Total Non-Current Liabilities (2016 - 2021) Analysis & Trends
Trafalgar International has reported Total Non-Current Liabilities for 6 years, with the latest figure at $460651.0 in Q1 2021.
- On a quarterly basis, Total Non-Current Liabilities fell 53.71% year-over-year to $460651.0 in Q1 2021; TTM through Mar 2021 was $460651.0, a 53.71% decrease from a year earlier, with the FY2020 full-year figure at $442467.0, down 72.03% from the prior year.
- Total Non-Current Liabilities was $460651.0 for Q1 2021 at Trafalgar International, up from $442467.0 in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $1.6 million in Q4 2019, with the low at -$205403.0 in Q4 2017.
- Average Total Non-Current Liabilities over 5 years is $511429.1, with a median of $459956.0 recorded in 2019.
- The sharpest annual moves came in 2017 and 2018: Total Non-Current Liabilities plunged 2437.31% in 2017, then surged 394.54% in 2018.
- Over 5 years, Total Non-Current Liabilities stood at -$205403.0 in 2017, then surged by 394.54% to $604999.0 in 2018, then surged by 161.46% to $1.6 million in 2019, then tumbled by 72.03% to $442467.0 in 2020, then advanced by 4.11% to $460651.0 in 2021.
- The last three Total Non-Current Liabilities figures came in at $460651.0 (Q1 2021), $442467.0 (Q4 2020), and $599261.0 (Q3 2020), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 105.99 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 106.45 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 16.16 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 48.34 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 100.86 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 32.04 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 1.53 Bn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 1.40 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 607.80 Mn |
| 10 | Trafalgar International | 217,335.05 | 217,335.05 | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2021 | 460,651.00 |
| Dec 31, 2020 | 442,467.00 |
| Sep 30, 2020 | 599,261.00 |
| Jun 30, 2020 | 774,453.00 |
| Mar 31, 2020 | 995,119.00 |
| Dec 31, 2019 | 1.58 Mn |
| Sep 30, 2019 | 508,947.00 |
| Jun 30, 2019 | 459,956.00 |
| Mar 31, 2019 | 409,882.00 |
| Dec 31, 2018 | 604,999.00 |
| Sep 30, 2018 | 401,874.00 |
| Jun 30, 2018 | 274,624.00 |
| Mar 31, 2018 | 217,776.00 |
| Dec 31, 2017 | -205,403.00 |
| Sep 30, 2017 | 144,976.00 |
| Dec 31, 2016 | 8,788.00 |